Kasper Katisko

发表

Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis

R. Vanninen, A. Hall, P. Hartikainen, 2020, Annals of clinical and translational neurology.

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

P. Hartikainen, S. Helisalmi, S. Herukka, 2019, Journal of Neurology.

Peripheral inflammatory markers and clinical correlations in patients with frontotemporal lobar degeneration with and without the C9orf72 repeat expansion

P. Hartikainen, S. Helisalmi, A. Koivisto, 2019, Journal of Neurology.

Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients

H. Soininen, A. Hall, P. Hartikainen, 2019, Journal of Alzheimer's disease : JAD.

Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia

R. Vanninen, P. Hartikainen, S. Heikkinen, 2022, Journal of Neurology.

Astrocytes and Microglia as Potential Contributors to the Pathogenesis of C9orf72 Repeat Expansion-Associated FTLD and ALS

M. Hiltunen, N. Huber, A. Remes, 2019, Front. Neurosci..

C9orf72 Repeat Expansion Does Not Affect the Phenotype in Primary Progressive Aphasia.

T. Hänninen, P. Hartikainen, A. Remes, 2020, Journal of Alzheimer's disease : JAD.

Modifiable potential risk factors in familial and sporadic frontotemporal dementia

P. Hartikainen, A. Koivisto, B. Borroni, 2022, Annals of clinical and translational neurology.

The Association Between Frontotemporal Lobar Degeneration and Bullous Pemphigoid.

P. Hartikainen, S. Helisalmi, A. Koivisto, 2018, Journal of Alzheimer's disease : JAD.

Cognitive impairment is not uncommon in patients with biallelic RFC1 AAGGG repeat expansion, but the expansion is rare in patients with cognitive disease.

K. Majamaa, Maria Lehtilahti, A. Remes, 2022, Parkinsonism & related disorders.

Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype

P. Hartikainen, S. Helisalmi, V. Leinonen, 2022, Alzheimer's Research & Therapy.

Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers

A. Remes, A. Haapasalo, Antti Cajanus, 2019, Front. Neurosci..

Comparison of Prodromal Symptoms of Patients with Behavioral Variant Frontotemporal Dementia and Alzheimer Disease

P. Hartikainen, A. Koivisto, A. Remes, 2020, Dementia and Geriatric Cognitive Disorders.

GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance

P. Hartikainen, S. Helisalmi, A. Koivisto, 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers

P. Hartikainen, S. Helisalmi, A. Koivisto, 2018, Journal of Neuroimmunology.

Traumatic Brain Injury Associates with an Earlier Onset in Sporadic Frontotemporal Dementia.

P. Hartikainen, A. Koivisto, B. Borroni, 2022, Journal of Alzheimer's disease : JAD.

Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals.

P. Hartikainen, V. Leinonen, S. Heikkinen, 2023, Journal of Alzheimer's Disease.

Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.

P. Hartikainen, A. Remes, A. Haapasalo, 2023, Journal of Alzheimer's disease : JAD.

Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers

P. Hartikainen, S. Helisalmi, A. Koivisto, 2018, Journal of Neuroimmunology.